Wild type BRAF malignant melanoma. Discontinue in cases of severe hypersensitivity & dermatologic reactions. QT prolongation. Ophthalmological reactions. Cutaneous & non-cutaneous squamous cell carcinoma. New primary melanoma. Prior or concurrent cancer associated w/ RAS mutation. Monitor liver enzymes & bilirubin prior to or during therapy, & as clinically indicated. Renal & hepatic impairment. Mild to severe photosensitivity. May affect ability to drive or operate machinery. Pregnancy & lactation. Non-Caucasian. Childn.
Increased & decreased plasma exposure of medicines metabolized by CYP1A2 & CYP3A4, respectively. INR monitoring concomitant w/ warfarin. P-gp & CYP3A4 inducers & inhibitors. Ipilimumab. Bupropion. A washout period of 8 days is necessary to avoid interaction w/ subsequent treatment.